CKD completes acquiring 3 exclusive licensed items

that it had signed exclusive sales agreements for in Korea

Completes reimbursement transfer process for Rivotril·Valium·Leustatin that it signed exclusive sales agreements for last year

Chong Kun Dang completed the acquisition process for the three items that it signed exclusive sales agreements for with foreign pharmaceutical companies last year.

 

All three items are known to have a prior history with Chong Kun Dang.

 

According to industry sources on the 11th, Chong Kun Dang has been receiving insurance reimbursement for the tranquilizer drug ‘Valium 5mg Tab.

 

(diazepam)’ starting this month.

 

The approval and reimbursement rights for the drug had previously been owned by Roche Korea.

 

However, after the global commercial rights of the drug were transferred from Roche to Pharmanovia, Chong Kun Dang signed an exclusive sales agreement for Valium in Korea with Pharmanovia in August last year.

 

Under the agreement, Chong Kun Dang transferred and acquired the license for Valium Tab.

 

5mg in Korea, and the reimbursement entity was also changed accordingly.

 

The sales right for the epilepsy treatment Rivotril (clonazepam) in Korea, whose license was also held by Roche Korea, had also been transferred to Chong Kun Dang through a transfer and acquisition process prior to Valium.

 

Accordingly, Rivotril’s reimbursement entity was switched from Roche Korea to Chong Kun Dang in March this year.

 

, whose sales rights was transferred from Roche Korea to Chong Kun Dang

In March last year, Chong Kun Dang acquired the exclusive domestic sales right for Rivotril from Cheplapharm, which owns the global commercial rights to Rivotril.

 

Cheplapharm had purchased the global commercial rights for Rivotril from Roche.

 

Both of the drugs had previously been sold by Chong Kun Dang under a joint sales agreement with Roche Korea.

 

Therefore, the interpretation is that the company acquired the exclusive domestic sales right of the two drugs to sell in its pre-established sales networks.

 

In June, the company also completed the transfer and acquisition of the domestic sales right for the anticancer drug ‘Leustatin Inj.

 

(cladribine) ' which had been previously owned by Janssen Korea.

 

Its global commercial rights are also owned by Pharmanovia, and an exclusive domestic sales agreement had been signed for the drug in October last year.

 

This is not the first time Chong Kun Dang had signed exclusive domestic sales agreements with new owners of drugs after the transfer of global commercial rights.

 

The company had previously signed an exclusive sales agreement and acquired the sales rights for the antihypertensive drug ‘Dilatrend’ and obesity treatment ‘Xenical' from Cheplapharm.

 

Chong Kun Dang owns the license and right to reimbursement for the drugs in Korea.